Tempus AI, Inc. (NASDAQ:TEM) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On.

On June 11, 2026, Tempus AI, Inc. (NASDAQ:TEM) announced that a multi-center validation of its artificial intelligence ECG software for predicting one-year atrial fibrillation or flutter risk was published in Heart Rhythm.

The company stated the study, titled “Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Flutter,” assessed its ECG-AF software across three geographically individual clinical sites. It analyzed data from 4,017 patients aged 65 and older without prior atrial fibrillation and without pacemaker or defibrillator use.

The firm reported that the ECG-AI-derived risk score surpassed pre-specified performance thresholds. The firm said the findings supported its 2024 FDA clearance for the technology.

Brandon Fornwalt, MD, PhD, SVP of Cardiology at Tempus and coauthor, said the study “marks an important step toward shifting cardiac care from late-stage intervention to early risk detection,” and stated the model “consistently predicts atrial fibrillation across varied clinical environments.”

The corporation also stated that ECG-AF is FDA-cleared for analyzing 12-lead ECGs to detect signs associated with AF within 12 months.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology business. It combines artificial intelligence and machine learning with healthcare. It focuses on establishing platforms for cancer, neuropsychiatry, cardiology, infectious illness, and radiology.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.